Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia.

Acute myeloid leukemia (AML) is a heterogeneous disease. A significant proportion of AML patients is refractory to clinical treatment or relapses. Our aim is to determine new potential AML clinical treatment prognosis markers. We investigated various cell fate and epigenetic regulation important gene level differences between refractory and responsive AML patient groups at diagnosis stage and after clinical treatment using RT-qPCR. We demonstrated that oncogenic MYC and WT1 and metabolic IDH1 gene expression was significantly higher and cell cycle inhibitor CDKN1A (p21) gene expression was significantly lower in refractory patients' bone marrow cells compared to treatment responsive patients both at diagnosis and after clinical treatment. Moreover, we determined that, compared to clinical treatment responsive patients, refractory patients possess a significantly higher gene expression of histone deacetylase 2 ( HDAC2 ) and epigenetic DNA modulator TET1 and a significantly lower gene expression of lysine acetyltransferase 6A ( KAT6A ) and nucleosome remodeling and deacetylase (NuRD) complex component GATAD2A . We suggest that MYC , WT1 , IDH1 , CDKN1A , HDAC2 , TET1 , KAT6A and GATAD2A gene expression changes might characterize refractory AML. Thus, they might be useful for AML prognosis. Additionally, we suggest that epigenetic modulation might be beneficial in combination with standard treatment.